Understanding how cell therapies help reduce HIV by looking at blood and immune signals
MultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.
Researchers will use blood samples and lab tests to find what in the body helps cell-based treatments lower HIV levels and restore the immune system in people with HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11523470 on NIH RePORTER |
What this research studies
This project looks at blood cells and plasma from people who received stem-cell transplants or genetically modified CD4 T-cell infusions to find what factors promote HIV reduction. Scientists will run many lab tests (genes, proteins, metabolites, and immune cell types) to map how the virus and immune system change after these therapies. They will compare samples and clinical data from three groups to find patterns linked to better long-term control of HIV and stronger antiviral immune responses. The goal is to identify blood markers or biological environments that help new immune cells take hold and limit HIV rebound when ART is stopped.
Who could benefit from this research
Good fit: Ideal participants are people with HIV who have received or are scheduled to receive allogeneic stem-cell transplants or autologous CCR5-modified CD4 T-cell infusions and can provide blood samples and medical records.
Not a fit: People without HIV or those not involved in cell-based therapy programs are unlikely to directly benefit from participation in this project.
Why it matters
Potential benefit: If successful, the work could guide safer, more effective cell therapies and point to blood markers that predict who might safely reduce or stop ART.
How similar studies have performed: A small number of HIV cures after CCR5Δ32/Δ32 stem-cell transplants and early trials of CCR5-modified T cells give encouraging but limited evidence that cell therapies can reduce the HIV reservoir.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Martinez-Picado, Javier — Emory University
- Study coordinator: Martinez-Picado, Javier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.